03.02.2010 • NewsDowprofit

Dow Chemical Profit Beats Street; Revenue Jumps

Dow Chemical posted a higher-than-expected fourth-quarter profit as volumes doubled in emerging markets and earnings from joint ventures mushroomed.

But while results were strong in countries like China and India, the largest U.S. chemical maker's prices and volumes fell in North America and Europe, an indication that the recession may not fully be over in those regions.

"We see demand in emerging geographies continuing to show sustained growth, which bodes well for global growth," Chief Executive Andrew Liveris said in a statement. "Growth will continue to lag in the U.S. and Europe, however, as high unemployment persists and questions about the sustainability of government stimulus spending remain."

Sales rose in four of Dow's seven business units, including basic plastics, which posted a 17% jump.

Dow said it had repaid a loan it used to buy rival Rohm & Haas last year and had cut its debt due in 2011 by 80 percent to $2.9 billion. It had $2.8 billion in cash on hand at the end of the quarter.

"Not only are they generating cash from their businesses, but also from asset sales, and they're using that cash to pay down debt," Alembic Global Advisors analyst Hassan Ahmed said. "I see the quarter as being a handy beat."

Company

The Dow Chemical Company

100 Larkin Center
48674 Midland

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.